Home ROVI announces the agreement with Hikma to distribute and market its Enoxaparin biosimilar

ROVI announces the agreement with Hikma to distribute and market its Enoxaparin biosimilar

Find out more …

General Information
of the Company
Financial and
Economic Information
Corporate Governance
Information for Investors
Contact
Read time: 0 mins
ROVI announces the agreement with Hikma to distribute and market its Enoxaparin biosimilar
https://rovi.es/sites/default/files/Press%20release_Hikma%20%281%29.pdf
Year: 
2018